Deltex Medical Regulatory News (DEMG)

2 June 2015

Deltex Medical Group plc

("Deltex Medical" or "the Company")

Board Changes

2 June 2015 - Deltex Medical Group plc, the global leader in oesophageal Doppler monitoring ("ODM"), is pleased to announce that, further to the announcement on 24 April 2015, Mr Christopher Jones has been appointed to the Board as a Non-Executive Director with effect from 1 June 2015.

Mr Jones has almost 25 years' of experience in the healthcare industry, both in the UK and importantly throughout the USA. He brings valuable experience to Deltex which will be of great assistance to the Company as it seeks to capitalise on its leading position in ODM in the USA.

Mr Jones worked in marketing leadership roles in the USA for Tyco Healthcare (now Covidien Inc) for nine years until 2004 and subsequently as Vice President of Marketing for the Nellcor monitoring and critical care division. Recently he was CEO of Tensys Medical Inc, a California based haemodynamic monitoring company until a successful sale of the business. From 2008 until April 2015 he was CEO of Glysure Limited, a UK based early stage monitoring company focused on critical care applications.

Full biographical details of Mr Jones are given in the announcement of 24 April 2015.

The following information regarding Mr Jones' appointment is required to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies:

Chris Jones does not currently hold shares in the Company.

Other directorships/partnerships held:

Save as disclosed above, there are no other details to be disclosed regarding Mr. Jones' appointment as required under paragraph (g) of Schedule 2 of the AIM Rules.

For further information, please contact:-

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

During 2013, the Company launched the CardioQ-ODM+ monitor that offers clinicians both of the two best-established technologies, Deltex Medical's ODM technology as well as Pulse Pressure Waveform Analysis ('PPWA') in one monitor. This allows clinicians to have unique real time insights into each of flow, pressure and resistance, the three pillars of haemodynamics.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and over 600,000 patients have been treated to date using Deltex Medical's single patient disposable probes.